WallStSmart
SGMT

Sagimet Biosciences Inc. Series A Common Stock

NASDAQ: SGMT · HEALTHCARE · BIOTECHNOLOGY

$7.69
-4.25% today

Updated 2026-06-05

Market cap
$403.24M
P/E ratio
P/S ratio
52.50x
EPS (TTM)
$-1.35
Dividend yield
52W range
$5 – $11
Volume
1.8M

Sagimet Biosciences Inc. Series A Common Stock (SGMT) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-10.55M$-10.42M$-21.71M$-24.49M$-23.77M$-42.44M$-45.65M
Capital expenditures$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Depreciation
Stock-based comp$2.99M$775000.00$1.90M$1.88M$4.99M$5.29M$6.45M
Free cash flow$-10.55M$-10.42M$-21.71M$-24.49M$-23.77M$-42.44M$-45.65M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does SGMT generate?

SGMT produced $-45.65M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is SGMT's balance sheet healthy?

SGMT holds $35.02M in cash and equivalents against — in long-term debt, on $111.38M of shareholder equity. That debt is best read against the cash flow the business throws off each year.